NCD (20.32) Transcatheter Aortic Valve Replacement (TAVR) - Revised

MLN Matters Number: MM11660 Revised
Related CR Release Date: June 10, 2020
Related CR Transmittal Number: R10179CP and R10179NCD
Related Change Request (CR) Number: 11660
Effective Date: June 21, 2019
Implementation Date: June 12, 2020

Note: CMS revised this article to reflect a revised CR 11660 issued on June 10, 2020. The CR revisions were for formatting purposes only and did not alter the substance of the article. In the article, CMS revised the CR release date, the CR transmittal numbers, and the web addresses of the transmittals. All other information remains the same.

CR 11660 informs MACs that effective June 21, 2019, the Centers for Medicare & Medicaid Services (CMS) will continue coverage of Transcatheter Aortic Valve Replacement (TAVR) under Coverage with Evidence Development (CED) when the procedure is provided for the treatment of symptomatic aortic valve stenosis and according to a Food & Drug Administration (FDA)-approved indication for use with an approved device, in addition to the coverage criteria outlined in the Medicare National Coverage Determinations (NCD) Manual (Pub. 100-03). CMS will also continue coverage of TAVR for uses that are not expressly listed as an FDA-approved indication in clinical studies that meet specific requirements and are approved by CMS.

View the complete CMS Medicare Learning Network (MLN) Matters (MM)11660.

 

            Last Updated Mon, 15 Jun 2020 16:23:55 +0000